The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
H-RAS and PIK3CA mutations and response to cetuximab in head and neck squamous cell carcinoma (HNSCC).
T. Rampias
No relevant relationships to disclose
A. Giagini
No relevant relationships to disclose
K. Florou
No relevant relationships to disclose
P. Gouveris
No relevant relationships to disclose
E. Vaja
No relevant relationships to disclose
N. Haralambakis
No relevant relationships to disclose
P. Katsaounis
No relevant relationships to disclose
D. G. Pectasides
No relevant relationships to disclose
T. Economopoulos
No relevant relationships to disclose
A. Psyrri
No relevant relationships to disclose